Keros Therapeutics vs Roivant Sciences
KROS and ROIV side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How KROS and ROIV compare
Roivant Sciences is the larger company, worth 125 times as much as Keros Therapeutics ($28.0B against $224M).
Roivant Sciences grew revenue faster over the last twelve months (−67.6% versus −93.7% for Keros Therapeutics).
Keros Therapeutics keeps more of each dollar of sales as profit, with a net margin of −572% compared with −3535% at Roivant Sciences.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | KROS | ROIV |
|---|---|---|
| Size and price | ||
| Market cap | $224M | $28.0B |
| Share price | $11.31 | $38.71 |
| Change, 1 year | −34.5% | 90.8% |
| Change, 5 years | −79.8% | 453% |
| Beta (5Y) | 2.04 | 0.42 |
| Employees | 78 | 721 |
| StockData Score | ||
| Total score | 7 | 7 |
| Valuation score | 1 (better) | 0 |
| Growth score | 0 | 0 |
| Performance score | 1 | 1 |
| Health score | 5 | 6 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 15.4× (better) | 3712× |
| P/B | 0.9× (better) | 6.6× |
| FCF yield | −21.6% | −2.9% (better) |
| Growth | ||
| Revenue growth (TTM) | −93.7% | −67.6% (better) |
| Revenue growth, 5Y average | – | −19.1% |
| Net income growth (TTM) | −543% | – |
| EPS growth (TTM) | −1287% | – |
| Profitability | ||
| Operating margin | −698% (better) | −7915% |
| Net margin | −572% (better) | −3535% |
| FCF margin | −334% (better) | −10901% |
| Return on equity | −17.2% | −6.2% (better) |
| Return on invested capital | −755% | −407% (better) |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Current ratio | 21.96 (better) | 16.72 |
| Altman Z-score | 2.67 | 44.02 (better) |
| Piotroski F-score | 6 (better) | 2 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 101% | 78.1% |
| Held by insiders | 53.3% | 13.9% |
| Insider net buying, 12 months | −$453K (better) | −$798M |
| Superinvestors holding | – | 1 |
| Short interest, % of float | 11.7% | 7.3% |
Go deeper
- KROS stock overview
- KROS income statement
- KROS valuation and score
- ROIV stock overview
- ROIV income statement
- ROIV valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.